3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
25
Vomiting
7
Triple Negative Breast Neoplasms
4
Nausea
4
Postoperative Nausea and Vomiting
3
Neoplasms
3
Multiple Myeloma
3
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Testicular Neoplasms
2
Sezary Syndrome
2
Primary Myelofibrosis
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pdgfra-Associated Chronic Eosinophilic Leukemia
2
Ovarian Neoplasms
2
Neuroblastoma
2
Myeloproliferative Disorders
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Neutrophilic, Chronic
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Myeloid, Acute
2
Interventions
Mastectomy, Modified Radical
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Systemic Inflammatory Response Syndrome
×
Dexamethasone
×
Breast
×
Clear all
NCT03125941
2019-12-02
DEX-MAS
Rigshospitalet, Denmark
Phase 4
Completed
130 enrolled
20 charts